Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical tr…
Biotechnology
US, Gaithersburg [HQ]
ACLX/Financial Reporting
Income Statements
5 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | 110.00 | |
|
EPS
|
-0.52 | -0.96 | -1.79 | -4.22 | -1.47 | |
| Diluted in mil. | -0.52 | -0.96 | -1.79 | -4.22 | -1.47 | |
|
Profit
|
- - | - - | -1.00 | -2.00 | 108.00 | |
| Gross Margin | - - | - - | - - | - - | 98.15 | |
| Pre Tax | -17.00 | -32.00 | -64.00 | -188.00 | -70.00 | |
| Profit Margin | - - | - - | - - | - - | -63.48 | |
| ETR | - - | - - | 1.60 | 1.37 | -0.95 | |
| Net | -17.00 | -32.00 | -63.00 | -186.00 | -70.00 | |
| Profit Margin | - - | - - | - - | - - | -64.08 | |
| EBITDA | -17.00 | -31.00 | -65.00 | -186.00 | -87.00 | |
| EBITDA Margin | - - | - - | - - | - - | -79.62 | |
| Operating Income | -17.00 | -32.00 | -65.00 | -191.00 | -89.00 | |
| Operating Margin | - - | - - | - - | - - | -81.47 | |
| Interest Income | - - | - - | - - | 4.00 | 23.00 | |
| Loss | -17.00 | -32.00 | -65.00 | -191.00 | -200.00 | |
| Cost of Revenue | - - | - - | -1.00 | -2.00 | -2.00 | |
|
Operating Expenses
|
-17.00 | -32.00 | -65.00 | -191.00 | -198.00 | |
| R&D | -15.00 | -25.00 | -46.00 | -149.00 | -133.00 | |
| G&A | -2.00 | -7.00 | -18.00 | -41.00 | -66.00 | |
| SG&A | -2.00 | -7.00 | -18.00 | -41.00 | -64.00 | |
| S&M | - - | - - | - - | - - | -2.00 | |
| Depreciation and Amortization | - - | - - | -1.00 | -1.00 | -2.00 | |
| Interest Expenses | - - | - - | - - | -1.00 | -3.00 | |
| Other Expenses | - - | - - | - - | -2.00 | -19.00 | |
|
WA Shares Outstanding
|
34.00 | 33.00 | 35.00 | 44.00 | 48.00 | |
| Diluted | 34.00 | 33.00 | 35.00 | 44.00 | 48.00 |